66 results on '"Newell-Price, John"'
Search Results
2. Improvements in diabetes and hypertension were sustained over long-term osilodrostat treatment in patients with Cushing's disease: A pooled analysis of LINC 3 and LINC 4
3. CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency
4. Morning cortisol levels in patients with established primary adrenal insufficiency
5. Retrospective study of steroid weaning in tertiary adrenal insufficiency comparing prednisolone and hydrocortisone
6. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control
7. Pro: Should diabetes insipidus be re-named?
8. Pooled analysis from two osilodrostat Phase III studies in Cushing's disease (LINC 3 and LINC 4): Clinical improvements according to urinary and late-night salivary cortisol levels
9. Pooled analysis of osilodrostat dosing across LINC 2, LINC 3 and LINC 4 in Cushing's disease
10. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control
11. Comparison of prednisolone and modified-release hydrocortisone capsules in the treatment of congenital adrenal hyperplasia: dose and disease control
12. Natural history of non-functioning pituitary microadenomas - results from the UK NFA consortium
13. Neuroendocrine tumour (NETs) patient experience of switching to generic somatostatin analogue during the COVID-19 pandemic
14. Screening for adrenal insufficiency using home waking salivary cortisone is accurate and lowers NHS costs
15. The pituitary patients' experiences pre and during the Covid-19 pandemic
16. Anticoagulation practice for venous thromboembolism prophylaxis in patients with Cushing’s Syndrome - a Society for Endocrinology survey of UK Centres
17. Fertility in congenital adrenal hyperplasia (CAH) patients on modified release hydrocortisone capsules (MRHC, Efmody)
18. Central diabetes insipidus from a patients′ perspective - from management to psychological co-morbidities and re-naming of the condition
19. Improved biochemical control with modified-release hydrocortisone overturns the impaired fludrocortisone effect in salt-wasting CAH patients
20. Osilodrostat therapy improves physical manifestations of hypercortisolism in patients with cushing's disease: findings from the phase III LINC 3 study
21. Impact of urinary and late-night salivary cortisol levels on clinical signs of hypercortisolism and quality of life in patients with Cushing's disease treated with osilodrostat
22. Modified release hydrocortisone capsules (MRHC, Efmody) improve control of congenital adrenal hyperplasia (CAH) on a lower glucocorticoid dose than standard treatment
23. Waking salivary cortisone as screening test for adrenal insufficiency
24. Sub acute thyroiditis following COVID-19 vaccination - case report and International survey
25. Change in androgens and adrenal hormones during long-term osilodrostat treatment in patients with Cushing's disease: Results from the Phase III, prospective LINC 3 study
26. Phase 3 and extension study of modified-release hydrocortisone in the treatment of congenital adrenal hyperplasia
27. Use of antisense oligonucleotides as a therapy for Cushings disease
28. DDAVP: diagnosis, dentition and arginine vasopressin
29. Osilodrostat is an effective and well-tolerated treatment option for patients with Cushings disease (CD): Final results from the LINC3 study
30. Durability of response and gender-based analysis from the LINC3 trial of osilodrostat in the treatment in cushing’s disease
31. A Phase III randomized, controlled trial of a modified-release hydrocortisone formulation in the treatment of classic congenital adrenal hyperplasia
32. Occult ectopic ACTH: controlling the disease to find the source, with a unique sequelae
33. Development of a mobile app for patients with neuroendocrine neoplasms: a collaborative project between United Kingdom NET Society and Neuroendocrine Tumour Patient Foundation
34. Sheffield experience of administering Lutathera as a day case treatment
35. Antisense oligonucleotides as a novel medical therapy for Cushing's disease
36. European observational study of ketoconazole for endogenous cushing's syndrome in collaboration with European registry on cushing's syndrome ERCUSYN: PASS ketoconazole study design and rationale
37. Osilodrostat provides clinical benefit over 48 weeks in patients with Cushing disease: Results from the LINC 3 study
38. Outcomes after primary treatment for Nelson's syndrome: a study from 13 UK centres
39. Pituitary apoplexy in a non-functioning pituitary adenoma: A case of favorable outcome in conservative management approach
40. Anti-POMC siRNA reduces ACTH secretion in an in vitro model of Cushing's disease
41. A novel non-invasive short synacthen test validated in healthy adult and paediatric populations
42. Late-night salivary cortisol (LNSC) levels in a Phase III study of long-acting pasireotide in patients with Cushing's disease (CD)
43. Long-term efficacy and safety of once-monthly pasireotide in patients with Cushing's disease: A Phase III extension study
44. Adrenal Incidentaloma
45. Diabetes mellitus and muscle weakness are independently associated with mortality in patients with Cushing's syndrome. Data from ERCUSYN
46. Cushing's research - Hot topics
47. Long-term safety of gamma knife radiosurgery (STRS) for acromegaly
48. Neuroendocrine tumours and the set up in the UK
49. Pasireotide: an effective treatment for resistant acromegaly
50. An unusual presentation of multiple endocrine neoplasia 1 (MEN1)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.